IL75179A - (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide,its preparation and pharmaceutical compositions containing it - Google Patents

(s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide,its preparation and pharmaceutical compositions containing it

Info

Publication number: IL75179A
Authority: IL; Israel
Prior art keywords: radical; oxo; alpha; ethyl; pyrrolidineacetamide
Prior art date: 1984-05-15

Application number

IL75179A

Other languages

English (en)

Other versions

IL75179A0 (en

Original Assignee

Ucb Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-05-15

Filing date

1985-05-13

Publication date

1988-05-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10560974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL75179(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1985-05-13 Application filed by Ucb Sa filed Critical Ucb Sa

1985-09-29 Publication of IL75179A0 publication Critical patent/IL75179A0/xx

1988-05-31 Publication of IL75179A publication Critical patent/IL75179A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrrole Compounds (AREA)
Detergent Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Cosmetics (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Seasonings (AREA)

IL75179A 1984-05-15 1985-05-13 (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide,its preparation and pharmaceutical compositions containing it IL75179A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB848412357A GB8412357D0 (en)	1984-05-15	1984-05-15	Pharmaceutical composition

Publications (2)

Publication Number	Publication Date
IL75179A0 IL75179A0 (en)	1985-09-29
IL75179A true IL75179A (en)	1988-05-31

Family

ID=10560974

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL75179A IL75179A (en)	1984-05-15	1985-05-13	(s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide,its preparation and pharmaceutical compositions containing it

Country Status (33)

Country	Link
US (3)	US4696943A (pl)
EP (1)	EP0162036B1 (pl)
JP (1)	JPH0629186B2 (pl)
KR (1)	KR920003819B1 (pl)
CN (1)	CN1015541B (pl)
AT (1)	ATE45567T1 (pl)
AU (1)	AU574465B2 (pl)
BG (2)	BG50156A3 (pl)
CA (1)	CA1235129A (pl)
CY (2)	CY1567A (pl)
DE (3)	DE3572348D1 (pl)
DK (1)	DK163501C (pl)
ES (2)	ES8608485A1 (pl)
FI (1)	FI80673C (pl)
GB (1)	GB8412357D0 (pl)
GE (1)	GEP20002001B (pl)
GR (1)	GR851155B (pl)
HK (1)	HK52391A (pl)
IE (1)	IE59950B1 (pl)
IL (1)	IL75179A (pl)
LT (1)	LT2584B (pl)
LU (2)	LU90615I2 (pl)
LV (1)	LV5233A3 (pl)
MY (2)	MY101726A (pl)
NL (1)	NL300028I2 (pl)
NO (2)	NO164534C (pl)
PL (2)	PL144346B1 (pl)
PT (1)	PT80460B (pl)
SA (1)	SA01210656A (pl)
SG (1)	SG80090G (pl)
SU (3)	SU1402260A3 (pl)
UA (1)	UA6158A1 (pl)
ZA (1)	ZA853635B (pl)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8827389D0 (en) *	1988-11-23	1988-12-29	Ucb Sa	Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
IT1231477B (it) *	1989-07-12	1991-12-07	Sigma Tau Ind Farmaceuti	(pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
GB9319732D0 (en)	1993-09-24	1993-11-10	Ucb Sa	Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
US6124473A (en) *	1998-05-08	2000-09-26	Ucb, S.A.	Process for preparing (s)- and (R)-α-ethyl-2-oxo-1-pyrrolidineacetamide
US6107492A (en) *	1998-05-08	2000-08-22	Ucb, S.A.	Process for the preparation of levetiracetam
EA002380B1 (ru) *	1999-07-21	2002-04-25	Российский Государственный Педагогический Университет Им. А.И.Герцена	Антиишемическое средство
EA002379B1 (ru) *	1999-07-21	2002-04-25	Российский Государственный Педагогический Университет Им. А.И.Герцена	Средство, обладающее антиишемической, гипотензивной и антигипоксической активностью
AR026610A1 (es)	1999-12-01	2003-02-19	Ucb Sa	Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
GB0004297D0 (en) *	2000-02-23	2000-04-12	Ucb Sa	2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en) *	2000-09-29	2004-02-03	Eastman Chemical Company	Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same
US7112612B2 (en)	2000-11-21	2006-09-26	Ucb S.A.	N-alkylated GABA compounds, processes for their preparation and their use as medicaments
CN1484527A (zh) *	2000-12-28	2004-03-24	��һ��ҩ��ʽ��	神经性疼痛治疗和预防药
JP2004523557A (ja) *	2001-02-23	2004-08-05	ジョンズ・ホプキンス・ユニバーシティ	チック、振せん、および関連疾患の治療
IL160045A0 (en) *	2001-08-10	2004-06-20	Ucb Sa	Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
JP4351909B2 (ja) *	2001-10-08	2009-10-28	ユセベファルマソシエテアノニム	薬剤を調製するための、２−オキソ−１−ピロリジン誘導体の使用
AU2003242538A1 (en) *	2002-05-14	2003-11-11	Ucb, S.A.	Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
WO2004069796A2 (en) *	2003-02-03	2004-08-19	Teva Pharmaceutical Industries Ltd.	Process for producing levetiracetam
ES2214147B1 (es)	2003-02-28	2005-10-01	Farma-Lepori S.A.	Procedimiento de obtencion de un agente antiepileptico.
WO2004083180A1 (en) *	2003-03-18	2004-09-30	Hetero Drugs Limited	Novel crystalline forms of levetiracetam
EP1663968A1 (en) *	2003-09-05	2006-06-07	Ranbaxy Laboratories Limited	Process for the preparation of pure levetiracetam
EA010306B1 (ru) *	2003-09-24	2008-08-29	Юсб, С.А.	Способ получения производных 2-оксо-1-пирролидина
CA2546970C (en)	2003-12-02	2011-04-26	Ucb, S.A.	Imidazole derivatives, processes for preparing them and their uses
US7531673B2 (en)	2004-02-18	2009-05-12	Dr. Reddy's Laboratories Limited	Preparation of amino acid amides
CA2488325C (en) *	2004-11-22	2010-08-24	Apotex Pharmachem Inc.	Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
NZ556630A (en) *	2005-01-27	2010-12-24	Alembic Ltd	Extended release formulation of levetiracetam including a hydrophilic rate controlling polymer
US20070298098A1 (en) *	2005-02-16	2007-12-27	Elan Pharma International Limited	Controlled Release Compositions Comprising Levetiracetam
WO2006088864A1 (en) *	2005-02-16	2006-08-24	Elan Pharma International Limited	Controlled release compositions comprising levetiracetam
WO2006090265A2 (en) *	2005-02-28	2006-08-31	Ranbaxy Laboratories Limited	Processes for the preparation of levetiracetam, its intermediate and the use of levetiracetam in pharmaceutical compositions
EP1863761A1 (en) *	2005-03-10	2007-12-12	Rubamin Limited	Process for preparing levetiracetam
US8216611B2 (en)	2005-03-30	2012-07-10	Mylan Pharmaceuticals Ulc	Combined-step process for pharmaceutical compositions
EP1879861A2 (en) *	2005-04-01	2008-01-23	Rubamin Laboratories Limited	Process for preparing levetiracetam and racemization of (r)- and (s)-2-amino butynamide and the corresponding acid derivatives
JP2008542322A (ja)	2005-06-01	2008-11-27	ユセベファルマソシエテアノニム	２−オキソ−１−ピロリジン誘導体
PL1909764T3 (pl) *	2005-07-26	2015-03-31	Ucb Pharma Sa	Kompozycje farmaceutyczne zawierające lewetyracetam i sposób ich wytwarzania
US8338621B2 (en)	2005-12-21	2012-12-25	Ucb S.A.	Process for the preparation of 2-oxo-1-pyrrolidine derivatives
CA2637925A1 (en) *	2006-01-24	2007-08-02	Teva Pharmaceutical Industries Ltd.	Levetiracetam formulations and methods for their manufacture
US20080014264A1 (en) *	2006-07-13	2008-01-17	Ucb, S.A.	Novel pharmaceutical compositions comprising levetiracetam
EP2049476A1 (en) *	2006-07-25	2009-04-22	ZaCh System S.p.A.	Process for the preparation of levetiracetam
WO2008021666A2 (en) *	2006-08-18	2008-02-21	Morton Grove Pharmaceuticals, Inc.	Stable liquid levetiracetam compositions and methods
CN101130504B (zh) *	2006-08-25	2010-07-28	苏州雅本化学股份有限公司	经合成、拆分与消旋化制备手性药物左乙拉西坦中间体(s)-(+)-2-氨基丁酰胺盐酸盐的方法
EP1932922A1 (de) *	2006-12-13	2008-06-18	Desitin Arzneimittel GmbH	Schnelltest zum Nachweis von DNA-Sequenzen
WO2008077035A2 (en) *	2006-12-18	2008-06-26	Dr. Reddy's Laboratories Ltd.	Processes for the preparation of levetiracetam
CN101333180B (zh) *	2007-06-29	2011-05-18	浙江华海药业股份有限公司	一种制备左乙拉西坦中间体的方法
US20090082422A1 (en) *	2007-09-26	2009-03-26	Protia, Llc	Deuterium-enriched levetiracetam
WO2009050735A1 (en) *	2007-10-15	2009-04-23	Lupin Limited	A novel polymorph of levetiracetam and a process for its preparation
US20090263481A1 (en) *	2008-04-17	2009-10-22	Atul Vishvanath Patil	Levetiracetam formulations
US20100003322A1 (en) *	2008-07-03	2010-01-07	Lai Felix S	Enteric coated hydrophobic matrix formulation
EP2147911A1 (en)	2008-07-24	2010-01-27	ZaCh System S.p.A.	Process for the preparation of levetiracetam
US20100190752A1 (en)	2008-09-05	2010-07-29	Gruenenthal Gmbh	Pharmaceutical Combination
CN107243007A (zh) *	2008-10-16	2017-10-13	约翰斯.霍普金斯大学	改善认知功能的方法和组合物
EP2179725A1 (en)	2008-10-23	2010-04-28	LEK Pharmaceuticals D.D.	Pharmaceutical composition comprising levetiracetam
US8722715B2 (en) *	2008-11-07	2014-05-13	NovaBay Pharmaceuticals	Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions
US20100172979A1 (en) *	2008-12-24	2010-07-08	Zhongshui Yu	Controlled-release formulations
US20100159009A1 (en) *	2008-12-24	2010-06-24	Zhongshui Yu	Controlled-release formulations
WO2010132693A2 (en)	2009-05-13	2010-11-18	Nektar Therapeutics	Oligomer-containing pyrrolidine compounds
CN101885696A (zh) *	2009-05-14	2010-11-17	上海华理生物医药有限公司	一种合成高纯度左乙拉西坦的方法
WO2011015349A2 (en)	2009-08-07	2011-02-10	Ucb Pharma, S.A.	Methods for enhancing the cognitive function
EP2298290A1 (en)	2009-09-16	2011-03-23	LEK Pharmaceuticals d.d.	Controlled release composition comprising levetiracetam
US7939676B2 (en) *	2009-09-17	2011-05-10	Zach System S.P.A.	Process for the preparation of levetiracetam
WO2011047860A1 (en)	2009-10-23	2011-04-28	Ucb Pharma, S.A.	2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives
CN102905532A (zh) *	2010-02-09	2013-01-30	约翰斯.霍普金斯大学	用于改善认知功能的方法和组合物
CN102884179A (zh)	2010-02-26	2013-01-16	加利福尼亚大学董事会	用于制备l-高丙氨酸的组合物和方法
EP2563340A2 (en)	2010-04-26	2013-03-06	Mahmut Bilgic	Water soluble pharmaceutical composition
US9333175B2 (en)	2010-06-16	2016-05-10	Mylan Inc.	Controlled release levetiracetam formulations and methods for producing the same
EP2492354A1 (en)	2011-02-23	2012-08-29	Institut National De La Recherche Agronomique (INRA)	Method for identifying compounds useful in the treatment of photosensitive reflex epilepsy
DK2699581T3 (en)	2011-04-18	2016-01-11	Ucb Biopharma Sprl	2-oxo-1-IMIDAZOLIDINYLIMIDAZOTHIADIAZOLDERIVATIVER
EP2524910A1 (en)	2011-05-17	2012-11-21	DSM IP Assets B.V.	Process for the resolution of aminobutyramide
CN102382027B (zh) *	2011-09-20	2013-11-13	浙江江北药业有限公司	一种左乙拉西坦的制备方法
CN102617436B (zh) *	2012-03-20	2014-02-12	浙江洪波化工有限公司	2-(2-氧代吡咯烷基）丁酰胺的制备方法
CN102633675A (zh) *	2012-04-10	2012-08-15	南京大学	一种dl-2-氨基丁酰胺制备方法
CN102675181B (zh) *	2012-06-07	2013-11-20	北京师宏药物研制中心	一种左乙拉西坦的制备方法
CN102702063B (zh) *	2012-06-15	2013-09-04	孙威	一种左乙拉西坦制备方法
WO2014012563A1 (en)	2012-07-20	2014-01-23	Ucb Pharma, S.A.	Compounds for enhancing the cognitive function
CA2891122C (en)	2012-11-14	2021-07-20	The Johns Hopkins University	Methods and compositions for treating schizophrenia
CN103012190B (zh) *	2012-12-05	2015-03-18	江苏拜克新材料有限公司	一种s-2-氨基丁酰胺盐酸盐的合成方法
US9339489B2 (en)	2013-03-15	2016-05-17	Aprecia Pharmaceuticals Company	Rapid disperse dosage form containing levetiracetam
DK2968220T3 (da)	2013-03-15	2021-06-14	Agenebio Inc	Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
AU2014228990B2 (en)	2013-03-15	2017-02-02	Aprecia Pharmaceuticals LLC	Rapid disperse dosage form containing levetiracetam
US10806717B2 (en)	2013-03-15	2020-10-20	The Johns Hopkins University	Methods and compositions for improving cognitive function
KR102414246B1 (ko)	2014-01-21	2022-06-27	얀센 파마슈티카 엔.브이.	대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
HUE045610T2 (hu)	2014-01-21	2020-01-28	Janssen Pharmaceutica Nv	2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk
CN103922988A (zh) *	2014-04-29	2014-07-16	苏州天马精细化学品股份有限公司	一种左乙拉西坦粗品的纯化方法
CN103910649A (zh) *	2014-04-29	2014-07-09	苏州天马精细化学品股份有限公司	一种左乙拉西坦中间体（s）-n-[1-(氨基羰基)丙基]-4-氯代丁酰胺的合成方法
CN104860863B (zh) *	2015-04-10	2017-06-20	惠州信立泰药业有限公司	左乙拉西坦和含其的药物组合物
WO2016191288A1 (en)	2015-05-22	2016-12-01	Agenebio, Inc.	Extended release pharmaceutical compositions of levetiracetam
EP3397253A1 (en)	2015-12-30	2018-11-07	Adamas Pharmaceuticals, Inc.	Methods and compositions for the treatment of seizure-related disorders
CN106432032B (zh) *	2016-09-14	2019-07-12	苏州天马药业有限公司	一种左乙拉西坦的制备方法
CN106591179B (zh) *	2016-12-05	2018-07-03	长兴制药股份有限公司	甲基包囊菌及其在选择性拆分制备(S)-α-乙基-2-氧-1-吡咯烷乙酸盐上的应用
MY199913A (en)	2016-12-16	2023-11-29	Idorsia Pharmaceuticals Ltd	Pharmaceutical combination comprising a t-type calcium channel blocker
CN108503610B (zh)	2017-02-24	2019-09-13	北京艾百诺医药股份有限公司	一种光学纯的(r)-4-正丙基-二氢呋喃-2(3h)-酮的制备方法
CN107337628B (zh) *	2017-08-10	2022-02-08	浙江华海药业股份有限公司	一种制备左乙拉西坦的方法
TWI826531B (zh)	2018-09-21	2023-12-21	南韓商愛思開生物製藥股份有限公司	具有㗁二唑之化合物及包含該化合物之醫藥組合物
CN110003074A (zh)	2019-04-23	2019-07-12	浙江华海药业股份有限公司	一种左乙拉西坦中间体的制备方法
TW202114655A (zh)	2019-08-14	2021-04-16	瑞士商辛鐵堤卡公司	左乙拉西坦(levetiracetam)之鞘內投藥
US11384050B1 (en)	2021-02-03	2022-07-12	Vitaworks Ip, Llc	Method for preparing levetiracetam and intermediates thereof
JP2024508052A (ja)	2021-02-26	2024-02-21	シンデシセラピューティクスソシエテアノニム	認知障害の治療のための化合物
US20240368082A1 (en) *	2023-05-05	2024-11-07	Suzhou Brighthope Pharmatech Co., Ltd	Process for the production of levetiracetam and intermediate thereof
US20240368080A1 (en) *	2023-05-05	2024-11-07	Suzhou Brighthope Pharmatech Co., Ltd	Process for the production of levetiracetam and intermediate thereof
US20240368081A1 (en) *	2023-05-05	2024-11-07	Suzhou Brighthope Pharmatech Co., Ltd	Process for the production of levetiracetam and intermediate thereof
US20240409511A1 (en) *	2023-06-12	2024-12-12	Suzhou Brighthope Pharmatech Co., Ltd	Process for the production of levetiracetam and intermediates thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1309692A (en) *	1970-02-13	1973-03-14	Ucb Sa	N-substituted lactams
GB1583871A (en) *	1976-10-19	1981-02-04	Ucb Sa	Anti-aggregants
FR2418790A1 (fr) *	1978-03-02	1979-09-28	Philagro Sa	Nouveaux derives de pyrrolidinone-2 et compositions herbicides les contenant
GB8412358D0 (en) *	1984-05-15	1984-06-20	Ucb Sa	Pharmaceutical composition

1984
- 1984-05-15 GB GB848412357A patent/GB8412357D0/en active Pending
1985
- 1985-05-04 BG BG089449A patent/BG50156A3/xx unknown
- 1985-05-13 GR GR851155A patent/GR851155B/el unknown
- 1985-05-13 IL IL75179A patent/IL75179A/xx not_active IP Right Cessation
- 1985-05-13 FI FI851875A patent/FI80673C/fi not_active IP Right Cessation
- 1985-05-14 UA UA3968802A patent/UA6158A1/uk unknown
- 1985-05-14 DE DE8585870069T patent/DE3572348D1/de not_active Expired
- 1985-05-14 DE DE2000175021 patent/DE10075021I1/de active Pending
- 1985-05-14 DE DE2001199005 patent/DE10199005I2/de active Active
- 1985-05-14 IE IE119385A patent/IE59950B1/en not_active IP Right Cessation
- 1985-05-14 PT PT80460A patent/PT80460B/pt unknown
- 1985-05-14 AT AT85870069T patent/ATE45567T1/de active
- 1985-05-14 DK DK212985A patent/DK163501C/da not_active IP Right Cessation
- 1985-05-14 PL PL1985253374A patent/PL144346B1/pl unknown
- 1985-05-14 CA CA000481512A patent/CA1235129A/en not_active Expired
- 1985-05-14 ZA ZA853635A patent/ZA853635B/xx unknown
- 1985-05-14 ES ES543124A patent/ES8608485A1/es not_active Expired
- 1985-05-14 ES ES000551428A patent/ES8704893B9/es not_active Expired - Fee Related
- 1985-05-14 EP EP85870069A patent/EP0162036B1/fr not_active Expired
- 1985-05-14 AU AU42530/85A patent/AU574465B2/en not_active Expired
- 1985-05-14 PL PL1985257385A patent/PL147386B1/pl unknown
- 1985-05-14 SU SU853898053A patent/SU1402260A3/ru active
- 1985-05-14 BG BG070238A patent/BG47497A3/xx unknown
- 1985-05-14 JP JP60102529A patent/JPH0629186B2/ja not_active Expired - Fee Related
- 1985-05-14 US US06/733,790 patent/US4696943A/en not_active Expired - Lifetime
- 1985-05-14 NO NO851933A patent/NO164534C/no active Protection Beyond IP Right Term
- 1985-05-15 KR KR1019850003322A patent/KR920003819B1/ko not_active IP Right Cessation
- 1985-07-10 CN CN85105301A patent/CN1015541B/zh not_active Expired
- 1985-10-25 SU SU853968802A patent/SU1430392A1/ru active
1986
- 1986-08-13 SU SU864027938A patent/SU1428195A3/ru active
1987
- 1987-03-12 US US07/025,277 patent/US4837223A/en not_active Expired - Lifetime
- 1987-04-20 MY MYPI87000507A patent/MY101726A/en unknown
- 1987-04-20 MY MYPI87000506A patent/MY101725A/en unknown
1989
- 1989-02-16 US US07/311,631 patent/US4943639A/en not_active Expired - Lifetime
1990
- 1990-10-02 SG SG800/90A patent/SG80090G/en unknown
1991
- 1991-07-11 HK HK523/91A patent/HK52391A/xx not_active IP Right Cessation
- 1991-12-20 CY CY1567A patent/CY1567A/xx unknown
1993
- 1993-05-19 LV LV930379A patent/LV5233A3/xx unknown
- 1993-08-17 LT LTRP873A patent/LT2584B/xx not_active IP Right Cessation
1999
- 1999-09-03 GE GEAP19994979A patent/GEP20002001B/en unknown
2000
- 2000-07-31 LU LU90615C patent/LU90615I2/fr unknown
- 2000-11-17 NL NL300028C patent/NL300028I2/nl unknown
- 2000-11-30 LU LU90682C patent/LU90682I2/fr unknown
2001
- 2001-01-20 SA SA01210656A patent/SA01210656A/ar unknown
- 2001-05-25 NO NO2001008C patent/NO2001008I2/no unknown
2004
- 2004-10-27 CY CY200400007C patent/CY2004007I1/el unknown

Also Published As

Publication number	Publication date
US4943639A (en)	1990-07-24
FI80673C (fi)	1990-07-10
GB8412357D0 (en)	1984-06-20
KR850008336A (ko)	1985-12-16
SA01210656A (ar)	2005-12-03
AU4253085A (en)	1986-11-20
LU90682I2 (fr)	2001-01-30
UA6158A1 (uk)	1994-12-29
CY1567A (en)	1991-12-20
SU1428195A3 (ru)	1988-09-30
LV5233A3 (lv)	1993-10-10
JPS60252461A (ja)	1985-12-13
NO851933L (no)	1985-11-18
DE10075021I1 (de)	2000-10-19
DE3572348D1 (de)	1989-09-21
CY2004007I2 (el)	2009-11-04
IE851193L (en)	1985-11-15
MY101726A (en)	1992-01-17
SU1402260A3 (ru)	1988-06-07
FI851875A0 (fi)	1985-05-13
IL75179A0 (en)	1985-09-29
ATE45567T1 (de)	1989-09-15
NO2001008I2 (no)	2005-05-30
DE10199005I1 (de)	2001-07-12
US4696943A (en)	1987-09-29
GEP20002001B (en)	2000-03-10
PL257385A1 (en)	1986-10-07
GR851155B (pl)	1985-11-25
CA1235129A (en)	1988-04-12
US4837223A (en)	1989-06-06
DK212985A (da)	1985-11-16
PL253374A1 (en)	1986-05-06
ZA853635B (en)	1985-12-24
NL300028I2 (nl)	2001-06-01
ES8608485A1 (es)	1986-06-16
ES543124A0 (es)	1986-06-16
PT80460B (pt)	1987-08-19
EP0162036B1 (fr)	1989-08-16
AU574465B2 (en)	1988-07-07
NO164534B (no)	1990-07-09
DE10199005I2 (de)	2002-03-14
FI851875L (fi)	1985-11-16
MY101725A (en)	1992-01-17
EP0162036A1 (fr)	1985-11-21
LT2584B (lt)	1994-03-25
KR920003819B1 (ko)	1992-05-15
IE59950B1 (en)	1994-05-04
BG50156A3 (en)	1992-05-15
NL300028I1 (nl)	2001-02-01
CN85105301A (zh)	1987-01-14
JPH0629186B2 (ja)	1994-04-20
BG47497A3 (en)	1990-07-16
SG80090G (en)	1990-11-23
DK163501B (da)	1992-03-09
SU1430392A1 (ru)	1988-10-15
NO164534C (no)	1990-10-17
PL144346B1 (en)	1988-05-31
DK163501C (da)	1992-07-27
HK52391A (en)	1991-07-19
CY2004007I1 (el)	2009-11-04
ES8704893A1 (es)	1987-04-16
FI80673B (fi)	1990-03-30
DK212985D0 (da)	1985-05-14
ES8704893B9 (es)	2012-02-07
CN1015541B (zh)	1992-02-19
PT80460A (fr)	1985-06-01
LU90615I2 (fr)	2000-10-02
PL147386B1 (en)	1989-05-31

Publication	Publication Date	Title
AU574465B2 (en)	1988-07-07	(s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
AU574175B2 (en)	1988-06-30	(r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide

Legal Events

Date	Code	Title
1999-10-28	KB	Patent renewed
2001-04-30	HE	Change of address of proprietor(s)
2003-07-06	KB	Patent renewed
2006-12-27	EXTN	Extension order renewed
2008-12-29	EXP	Patent expired